Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer

Cytotoxic chemotherapy remains an important treatment for patients with non-small cell lung cancer (NSCLC) either alone or in combination with immunotherapy. Studies demonstrating the efficacy of first line treatment with immune checkpoint inhibitors (ICI) alone and in combination with chemotherapy have led to new first-line treatment options for patients with NSCLC [1 –3]. Carboplatin, pembrolizumab and either paclitaxel or nab-paclitaxel are now standard first line options for patients with lung squamous cell carcinoma (LSCC) [4].

Source: Lung Cancer - June 16, 2019 Category: Cancer & Oncology Authors: Dwight H. Owen, Terence M. Williams, Erin M. Bertino, Xiaokui Mo, Amy Webb, Catherine Schweitzer, Tom Liu, Sameek Roychowdhury, Cynthia D. Timmers, Gregory A Otterson Source Type: research